Every step, jump or dance move depends on a quiet partnership between muscles and the nerves that control them. When that partnership fails, the result can be a serious neuromuscular disease. A team at the Max-Delbrück Center in Germany has grown tiny human neuromuscular organoids in the lab that organise themselves and recreate this link, opening a path from a curiosity-driven question to future treatments – and at the end you can check what kind of lab explorer you are.
The starting point of the GPSorganoids project was a deceptively simple question. How do skeletal muscles and the nervous system develop in a coordinated way, so that they eventually form the functional circuits that allow people to run, jump and dance? Movement looks effortless from the outside, but it relies on nerve cells and muscle fibres growing up side by side and learning to communicate.
Understanding that process is fundamental research: the aim is first to find out how something works. As the project showed, however, answers to such basic questions can quickly become useful in medicine.
Neuromuscular diseases affect around 1 in 500 Europeans. In these conditions, the link between nerves and muscles is disrupted, and the consequences can be devastating. Two examples highlighted by the project are spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS).
To study such diseases properly and to look for ways to treat them, researchers need accurate models of the human neuromuscular system. The GPSorganoids team, supported by the European Research Council (ERC), set out to build exactly that kind of model.
The team is led by Mina Gouti, group leader at the Max-Delbrück Center for Molecular Medicine (MDC) in Germany, which hosts the project. Her group grew organoids – small, three-dimensional pieces of human tissue – that arrange themselves without being assembled piece by piece.
“We developed self-organising human neuromuscular organoids that faithfully recreate key functional interactions between spinal motor neurons and skeletal muscle,” says Gouti. In other words, the lab-grown tissue reproduces the connection between the nerve cells of the spinal cord that control movement and the muscles that carry it out.
Growing the organoids was only the first step. The researchers also brought bioengineering into the picture by applying controlled electrical stimulation to the neuromuscular organoid platform. This significantly enhanced the maturation and functionality of the organoids.
According to Gouti, the work demonstrates how combining developmental biology with bioengineering can produce human tissues that are more physiologically relevant – that is, closer to the way real tissue behaves in the human body. For researchers, this matters: the closer a model is to reality, the more its results can be trusted.
“The result is a powerful platform for studying neuromuscular development, uncovering disease mechanisms and evaluating potential therapies,” Gouti explains. The team also developed a self-organising human neuromuscular junction platform that allows for region-specific disease modelling. Taken together, the work offers several uses:
“Together, these complementary technologies provide physiologically relevant human models for understanding disease mechanisms, identifying new therapeutic targets and evaluating candidate therapies while creating scalable platforms that accelerate drug discovery,” remarks Gouti.
The original plan was to recreate the human neuromuscular system by harnessing the molecular cues of human development. Along the way, the team found something it had not expected: combining developmental biology with bioengineering could make the organoids even more physiologically relevant.
This is where curiosity-driven research paid off. “The ERC provided us with the freedom to pursue these unexpected directions in bioengineering, allowing us to not only answer the questions we originally asked, but also build entirely new research directions that will ultimately benefit society,” concludes Gouti. The project received EUR 2 799 375 from the ERC and runs from January 2022 to December 2027.
The next step goes beyond the basic science. Thanks to an ERC Proof of Concept grant, the team is working to automate the generation and analysis of neuromuscular organoids using robotics and advanced imaging. Automation should help produce standardised models and move the approach closer to personalised medicine.
“I am confident that our work will help researchers worldwide better understand neuromuscular diseases and accelerate the development of new therapies for treating them,” notes Gouti.
The GPSorganoids project began with a question about how nerves and muscles develop together and ended up with self-organising human neuromuscular organoids. Electrical stimulation made them more mature, patient-derived stem cells made them useful for studying SMA, and automation could make them easier to use at scale. The organoids act as a bridge between a fundamental question and the search for therapies for diseases that affect around 1 in 500 Europeans.
5 questions · one minute
EN 
CS
DE
ES
FR
HU
IT
PL
PT
РУ
SK
TR
УК
AR
中文